1.65
+0.04(+2.48%)
Currency In USD
| Previous Close | 1.61 |
| Open | 1.61 |
| Day High | 1.65 |
| Day Low | 1.57 |
| 52-Week High | 2.01 |
| 52-Week Low | 0.24 |
| Volume | 891,249 |
| Average Volume | 1.63M |
| Market Cap | 117.35M |
| PE | -3.3 |
| EPS | -0.5 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 0.93 |
| Change | 0.04 |
If you invested $1000 in Ovid Therapeutics Inc. (OVID) since IPO date, it would be worth $134.69 as of January 14, 2026 at a share price of $1.65. Whereas If you bought $1000 worth of Ovid Therapeutics Inc. (OVID) shares 5 years ago, it would be worth $642.02 as of January 14, 2026 at a share price of $1.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 03, 2025 11:05 AM GMT
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrantsNEW YORK, Oct. 03, 2025 (GLOBE NEWSWIR